Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Find generic entry opportunities
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Methods of treating autoimmune diseases caused by small intestinal bacterial overgrowth|
|Abstract:||Disclosed is a method of diagnosing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis an autoimmune disease. Also disclosed is a method of treating these autoimmune diseases, which involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of antimicrobial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. Also disclosed is a kit for the diagnosis or treatment of autoimmune diseases.|
|Inventor(s):||Lin; Henry C. (Albuquerque, NM), Pimentel; Mark (Los Angeles, CA)|
|Assignee:||Cedars-Sinai Medical Center (Los Angeles, CA)|
|Filing Date:||Mar 28, 2011|
|Claims:||1. A method of treating an autoimmune disease in a subject having small intestinal bacterial overgrowth and a symptom associated with a suspected diagnosis of the autoimmune disease, comprising: providing a composition comprising an antimicrobial agent or a probiotic agent; and; administering the composition to the subject to at least partially eradicate small intestinal bacterial overgrowth and the symptom is improved. |
2. The method of claim 1, further comprising: detecting the presence of small intestinal bacterial overgrowth in the subject.
3. The method of claim 1, wherein the autoimmune disease is multiple sclerosis or systemic lupus erythematosus.
4. The method of claim 1, wherein the antimicrobial agent is selected from the group consisting of neomycin, metronidazole, teicoplanin, ciprofloxacin, doxycycline, tetracycline, augmentin, cephalexin, penicillin, ampicillin, kanamycin, rifamycin, rifaximin, vancomycin, and combinations thereof.
5. The method of claim 1, wherein the antimicrobial agent is rifaximin.
6. The method of claim 1, further comprising administering to said human subject an anti-inflammatory cytokine , substantially simultaneously with or after at least partially eradicating small intestinal bacterial overgrowth in the human subject.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.